Glucomannan / Konjac Glucomannan (KGM) for Weight Loss

Verdict: No reliable weight-loss benefit; safety caveats

Despite an EU-authorized health claim, the largest and most rigorous trials show glucomannan produces no clinically meaningful weight loss versus placebo. It is not a dependable weight-loss aid, carries documented choking and gut-obstruction risks, and should not replace diet, exercise, or evidence-based treatment.

D 🔴 D Counter-Evidence Disputed

🔬Why this grade7-layer evidence engine

The clinical-trial record is split but leans negative. The largest and highest-quality meta-analysis (Onakpoya 2014, 9 RCTs, n=531; PMID 24533610) found no significant effect on body weight (-0.22 kg, not significant), and a systematic review of adults and children (Zalewski 2015; PMID 26059384) concluded there is no clinically meaningful benefit. A pediatric RCT (PMID 8247594) was likewise negative. Only an older fibre meta-analysis (Sood 2008; PMID 18842808, about -0.79 kg) and one small 1984 trial (PMID 6096282) suggested a modest effect, so any real benefit is tiny and inconsistent.

Regulators disagree, which is why this grade is disputed. The EU's EFSA authorized a narrow weight-loss claim at 3 g/day taken with water before meals within a calorie-restricted diet. But the US FDA has approved no such claim and maintains an import alert on konjac mini-cup jellies over choking deaths, while WHO/JECFA judges konjac flour safe only as a food additive, not as a weight-loss therapy.

Clinical sources reinforce caution. Cleveland Clinic's obesity-medicine guidance advises against herbal weight-loss products including glucomannan, citing throat or intestinal blockage from tablets and interference with blood-sugar control; major US obesity societies do not endorse it. Net: at best a marginal, unreliable effect paired with real mechanical and drug-interaction risks, hence a Counter-Evidence (D) rating.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.35
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
D · Disputed
Confidence
75%
Broadly consistent
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)

How strongly each layer supports this effect

lower = less supportive
L5 Clinical bodiesAuthoritative stance
0.15
L2 PubMedPrimary literature
0.45
L3 MechanismPlausibility
0.45
L1 ExamineGlobal benchmark
0.50
L11 AI re-checkIndependent read
0.50
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.346
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高階證據未達主導 (0 positive vs 1 negative),由 raw_score 決定
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 1 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (5)L2 · primary research & systematic reviews

The efficacy of glucomannan supplementation in overweight and obesity: a systematic review and meta-analysis of randomized clinical trials
PMID: 24533610 2014 統合分析 n = 531
Finding: Onakpoya et al. meta-analysis of 9 RCTs found no statistically significant effect of glucomannan on body weight versus placebo (MD -0.22 kg, 95% CI -0.62 to 0.19, p=0.30); heterogeneity low.
🟢 High quality Academic Effect size: MD -0.22 kg (95% CI -0.62 to 0.19), NS
View on PubMed
Effect of fibre supplements on body weight: a meta-analysis of randomized controlled trials (Sood et al.)
PMID: 18842808 2008 統合分析
Finding: Sood et al. pooled analysis indicated glucomannan produced statistically significant weight loss vs placebo (WMD approximately -0.79 kg) alongside improvements in lipids; magnitude modest and clinical relevance limited.
Effect size: WMD ~ -0.79 kg vs placebo
View on PubMed
Effect of glucomannan on body weight in overweight and obese children and adults: systematic review of randomized controlled trials (Zalewski et al.)
PMID: 26059384 2015 系統性回顧
Finding: Zalewski et al. concluded current evidence does not support a clinically meaningful effect of glucomannan on body weight in overweight or obese adults or children; pediatric RCTs were small and inconsistent.
🟢 High quality Academic Effect size: No clinically meaningful effect
View on PubMed
Effect of glucomannan on obese patients: a clinical study
PMID: 6096282 1984 RCT (double-blind) n = 53
Finding: Small RCT reported greater weight loss with glucomannan vs placebo in moderately overweight adults at 8 weeks; effect modest and limited by sample size and short duration.
Effect size: Modest WMD favoring glucomannan
View on PubMed
Childhood obesity treatment: double blinded trial on dietary fibres (glucomannan) versus placebo
PMID: 8247594 1993 RCT (double-blind) n = 60
Finding: Pediatric RCT found no statistically significant difference between glucomannan and placebo for BMI z-score or body weight; some lipid endpoints improved.
Effect size: No significant difference in weight/BMI
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
These small cup-like products maintain their characteristics (i.e., shape, texture, firmness) and do not melt when placed in the mouth. An FDA Health Hazard Evaluation Board and physiologists with the Consumer Products Safety Commission (CPSC) assessed the products and concluded that the physical characteristics of the small cup-like candies (particularly, the packaging, shape, slipperiness, an… source↗
L4b EU EFSA
Supportive
L4d TW TFDA / 衛福部
Cautious
市售含蒟蒻成分果凍應於個別產品外包裝顯著標示警語:1.請勿以強吸一口整粒吞食。2.五歲以下幼兒請勿食用。3.老人及兒童食用時,請大人陪伴以匙分段進食。4.請細嚼慢嚥,以免噎到。5.嬉戲時請勿食用。6.請咀嚼,勿整粒吞食(擇一標示)。適用範圍包含剖面直徑4.5公分(含)以內球形或類似球形產品,及非球形直徑3.1公分(含)以內、入口後產品表面平順滑溜之果凍。自民國95年1月1日起實施(衛署食字第0940405150號,94年9月30日公告)。 source↗
L4e WHO
Neutral
The Committee concluded that the additional studies provided no evidence of adverse effects attributable to konjac flour in experimental animals. Metabolically, konjac flour behaves in the intestine in a similar way to other polysaccharide gums. ADI 'not specified' for konjac flour. source↗
L5a NIH Office of Dietary Supplements
Cautious
L5c Cleveland Clinic
Against
Glucomannan is a sugar made from the root of the konjac plant (Amorphophallus konjac). Glucomannan might work in the stomach and intestines by absorbing water to form a bulky fiber that treats constipation. It may also slow the absorption of sugar and cholesterol from the gut. Glucomannan tablets are not considered safe as they can sometimes cause blockages of the throat or intestines. Glucoman… source↗
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬5 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-weight-loss-INT-glucomannan-001 繁體中文版 →